Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Raptor Pharmaceutical Corp | d88907dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 10, 2015
RAPTOR PHARMACEUTICAL CORP.
(Exact name of registrant as specified in its charter)
| Delaware | 000-25571 | 86-0883978 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
7 Hamilton Landing, Suite 100
Novato, California 94949
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (415) 408-6200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01 | Other Events. |
On December 10, 2015, Raptor Pharmaceutical Corp. issued a press release announcing 36-month efficacy results from its Phase 2/3 clinical trial evaluating RP103 for the potential treatment of Huntington’s disease, conducted in collaboration with the Centre Hospitalier Universitaire d’Angers, France.
The Company will host an investor webcast and conference call on December 10, 2015 at 8:00 a.m. Eastern Time to discuss these results.
A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| Exhibit |
Exhibit Description | |
| 99.1 | Press Release issued by Raptor Pharmaceutical Corp., dated December 10, 2015. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: December 10, 2015 | RAPTOR PHARMACEUTICAL CORP. | |||||
| By: | /s/ Michael P. Smith | |||||
| Name: | Michael P. Smith | |||||
| Title: | Chief Financial Officer | |||||
Exhibit Index
| Exhibit No. |
Exhibit Description | |
| 99.1 | Press Release issued by Raptor Pharmaceutical Corp., dated December 10, 2015. | |